Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Carcinoma, Squamous Cell 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × Decitabine × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡